Malignant lymphoma of the vagina successfully treated with rituximab, adryamicin, cyclophosphamide, vincristine sulfate, and prednisolone

Purpose: Primary malignant lymphoma of the vagina is extremely rare. The most common histologic subtype is diffuse large B-cell lymphoma (DLBCL). We report a case of vaginal DLBCL successfully treated with chemotherapy consisting of rituximab, adryamicin, cyclophosphamide, vincristine sulfate, and prednisolone (R-CHOP), followed by pelvic irradiation. Case: A 44-year-old Japanese woman was admitted complaining of atypical genital bleeding and puruloid vaginal discharge. Gynecological examination showed an ulceration of the vaginal wall and a hard mass the size of a goose egg beneath the left vaginal wall, which had infiltrated to the left pelvic wall. The pathological diagnosis based on a punch biopsy taken from the vaginal tumor was non-Hodgkin's lymphoma. Based on immunohistochemical study, the tumor was subclassified as activated B-cell type DLBCL. The patient was diagnosed with Ann Arbor Stage TEA DLBCL and Stage III vaginal cancer, according to the International Federation of Gynecologists and Obstetricians (FIGO) classification system. She was successfully treated by six courses of R-CHOP, followed by radiation therapy. The patient is well without evidence of disease 13 months following the initial treatment. Conclusion: Little attention has been paid to the use of rituximab in addition to conventional chemotherapy and the importance of clinical and morphological subgrouping of DLBCL arising in the vagina. The present case indicates that the effects of rituximab on the prognosis of vaginal DLBCL must be evaluated, and that clinical use of immunophenotypic subgrouping should be considered for vaginal DLBCL.

Malignant lymphoma; Vagina; Chemotherapy; Radiation

[1] Chorlton I., Karnei R.F. Jr., King F.M., Norris H.J.: “Primary malignant reticuloendothelial disease involving the vagina, cervix, and corpus uteri”. Obstet. Gynecol., 1974, 44, 35.

[2] Harris N.L., Scully R.E.: “Malignant lymphoma and granulocytic sarcoma of the uterus and vagina. A clinicopathologic analysis of 27 cases”. Cancer, 1984, 53, 2530.

[3] Vang R., Medeiros L.J., Silva E.G., Gershenson D.M., Deavers M.: “Non-Hodgkin’s lymphoma involving the vagina: a clinicopathologic analysis of 14 patients”. Am. J. Surg. Pathol., 2000, 24, 719.

[4] Guarini A., Pavone V., Valentuino T., Rana A., Di Vagno G., Maiorano E., Liso V.: “Primary non-Hodgkin’s lymphoma of the vagina”. Leuk. Lymphoma, 1999, 35, 619.

[5] Vang R., Medeiros L.J., Fuller G.N., Sarris A.H., Deavers M.: “Non-Hodgkin’s lymphoma involving the gynecologic tract: a review of 88 cases”. Adv. Anat. Pathol., 2001, 8, 200.

[6] Domingo S., Perales A., Torres V., Alcaraz M.J., Pellicer A.: “Epstein-Barr virus positivity in primary vaginal lymphoma”. Gynecol. Oncol., 2004, 95, 719.

[7] Mahendran S.M.: “Primary non-Hodgkin’s lymphoma of the vagina masquerading as a uterine fibroid in pregnancy”. J. Obstet. Gynaecol., 2008, 28, 456.

[8] Ikuta A., Tanaka Y., Tsuzuki T., Tsuji S., Sumi G., Mizokami T. et al.: “Vaginal lymphoma with immune thrombocytopenic purpura: an unusual case report”. Case Rep. Oncol., 2010, 3, 397.

[9] Evans L.S., Hancock B.W.: “Non-Hodgkin lymphoma”. Lancet, 2003, 362, 139.

[10] Coffier B.: “Rituximab therapy in malignant lymphoma”. Oncogene, 2007, 26, 3603.

[11] Cohn D.E., Resnick K.E., Eaton L.A., deHart J., Zanagnolo V.: “Non-Hodgkin’s lymphoma mimicking gynecological malignancies of the vagina and cervix: a report of four cases”. Int. J. Gynecol. Cancer, 2007, 17, 274.

[12] Hussein I.Y., Said M.R., Macheta A., Joglekar V.: “Primary non- Hodgkin’s lymphoma of the vagina”. J. Obstet. Gynaecol., 2007, 27, 752.

[13] The Non-Hodgkin’s Lymphoma Classification Project: “A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma”. Blood, 1997, 89, 3909.

[14] The International Non-Hodgkin’s Lymphoma Prognostic Factors Project: “A predictive model for aggressive non-Hodgkin’s lymphoma”. N. Engl. J. Med., 1993, 329, 987.

[15] Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A. et al.: “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling”. Nature, 2000, 403, 503.

[16] Wright G., Tan B., Rosenwald A., Hurt E.H., Wiestner A., Staudt L.M. et al.: “A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma”. Proc. Natl. Acad. Sci USA, 2003, 100, 9991.

[17] Stein H., Warke R.A., Chan W.C., Jaffe E.S., Chan J.K.C., Gatter K.C., Campo E.: “Diffuse large B-cell lymphoma, not other specified”. In: Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., Vardiman J.W. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC, 2008, 233.

[18] Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Off G. et al.: “Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray”. Blood, 2004, 103, 275.

[19] Amen F., Horncastle D., Elderfield K., Banham A.H., Bower M., Macdonald D. et al.: “Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients”. Histopathology, 2007, 51, 70.

[20] Mounier N., Briere J., Gisselbrecht C., Emile J.F., Lederlin P., Sebban C. et al.: “Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)”. Blood, 2003, 101, 4279.

[21] Winter J.N., Weller E.A., Horning S.J., Krajewska M., Variakojis D., Habermann T.M. et al.: “Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study”. Blood, 2006, 107, 4207.